{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:51Z","timestamp":1793225991478,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["No. 2022ZSQN09"],"award-info":[{"award-number":["No. 2022ZSQN09"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["No. 2023ZYYS-016"],"award-info":[{"award-number":["No. 2023ZYYS-016"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["No. 2020ZSLC39"],"award-info":[{"award-number":["No. 2020ZSLC39"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","award":["No. 2020ZHZS02"],"award-info":[{"award-number":["No. 2020ZHZS02"]}],"id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-2019AZQN-1014"],"award-info":[{"award-number":["Y-2019AZQN-1014"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019087","name":"Shanghai Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines","doi-asserted-by":"publisher","award":["21PJD039"],"award-info":[{"award-number":["21PJD039"]}],"id":[{"id":"10.13039\/501100019087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05617-6","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:03:38Z","timestamp":1724929418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"5617_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"5617_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"5617_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21(7):495\u2013508.","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"5617_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"5617_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504\u201315.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"5617_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6): e002435.","journal-title":"J Immunother Cancer"},{"issue":"36","key":"5617_CR7","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5617_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001887","volume":"8","author":"J Cautela","year":"2020","unstructured":"Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8(2): e001887.","journal-title":"J Immunother Cancer"},{"key":"5617_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021;93:87\u201394.","journal-title":"Eur J Intern Med"},{"issue":"24","key":"5617_CR10","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"5617_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.","journal-title":"Nat Rev Dis Primers"},{"key":"5617_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Gon\u00e7alves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.","journal-title":"Front Immunol"},{"issue":"18","key":"5617_CR13","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017;77(18):1987\u20132001.","journal-title":"Drugs"},{"issue":"18","key":"5617_CR14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"issue":"25","key":"5617_CR15","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"5","key":"5617_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"5617_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","volume":"160","author":"S Bishu","year":"2021","unstructured":"Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology. 2021;160(3):932\u20134.","journal-title":"Gastroenterology"},{"issue":"24","key":"5617_CR18","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1056\/NEJMc2002527","volume":"382","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Hudson M, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med. 2020;382(24):2374\u20135.","journal-title":"N Engl J Med"},{"key":"5617_CR19","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"5617_CR20","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2020","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020."},{"issue":"12","key":"5617_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"12","key":"5617_CR22","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27(12):1984\u20132009.","journal-title":"Protein Sci"},{"issue":"12","key":"5617_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5617_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"5617_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, S\u00e8ve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11): 102390.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"5617_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","volume":"161","author":"SC Sasson","year":"2021","unstructured":"Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, et al. Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology. 2021;161(4):1229-44.e9.","journal-title":"Gastroenterology"},{"issue":"10","key":"5617_CR27","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.3390\/cancers13102498","volume":"13","author":"D Finke","year":"2021","unstructured":"Finke D, Heckmann MB, Salatzki J, Riffel J, Herpel E, Heinzerling LM, et al. Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation. Cancers (Basel). 2021;13(10):2498.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"5617_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315.","journal-title":"Cancer Discov"},{"issue":"6","key":"5617_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201.","journal-title":"Cell Rep"},{"issue":"2","key":"5617_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"9","key":"5617_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"10","key":"5617_CR32","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","volume":"29","author":"N Jacquelot","year":"2019","unstructured":"Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, et al. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019;29(10):846\u201361.","journal-title":"Cell Res"},{"issue":"4","key":"5617_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/1535-7163.MCT-17-0667","volume":"17","author":"SP Pitroda","year":"2018","unstructured":"Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, et al. JAK2 inhibitor SAR302503 abrogates PD-L1 expression and targets therapy-resistant non-small cell lung cancers. Mol Cancer Ther. 2018;17(4):732\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"5617_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1291106","volume":"6","author":"C Lu","year":"2017","unstructured":"Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. 2017;6(3): e1291106.","journal-title":"Oncoimmunology"},{"issue":"4","key":"5617_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"5617_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2021.07.023","volume":"157","author":"Q Liu","year":"2021","unstructured":"Liu Q, Yu Y, Lin J, Wang Y, Ai L, Li Q, et al. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. Eur J Cancer. 2021;157:10\u201320.","journal-title":"Eur J Cancer"},{"issue":"1","key":"5617_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard-2022-223357","volume":"82","author":"A Sepriano","year":"2023","unstructured":"Sepriano A, Kerschbaumer A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):107\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5617_CR38","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors In Patients With Inflammatory Bowel Diseases Or Other Immune-Mediated Diseases: A Systematic Review And Meta-Analysis. Gastroenterology. 2020;158(6):1554-73.e12.","journal-title":"Gastroenterology"},{"issue":"4","key":"5617_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"42","key":"5617_CR40","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","volume":"42","author":"C Baldini","year":"2021","unstructured":"Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J. 2021;42(42):4389\u2013400.","journal-title":"Eur Heart J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05617-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:07:33Z","timestamp":1724929653000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05617-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5617"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05617-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Zhongshan Hospital affiliated to Fudan University (Approval No. B2023-178). All patients gave informed consent to participate in the study before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"803"}}